Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$7.30 +2.8%	$7.46	$5.90 ▼ $29.61	$535.97M	2.22	2.17 million shs	840,670 shs
BLTE Belite Bio	$65.20 +2.8%	$62.90	$43.70 ▼ $86.53	$2.08B	-1.49	44,056 shs	27,002 shs
HRMY Harmony Biosciences	$37.29 +1.8%	$34.30	$26.47 ▼ $41.61	$2.15B	0.84	655,532 shs	536,329 shs
SRPT Sarepta Therapeutics	$20.06 -2.5%	$18.65	$10.41 ▼ $144.22	$1.96B	0.46	6.20 million shs	16.66 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	-0.56%	+0.14%	-5.59%	+9.74%	-71.60%
BLTE Belite Bio	+2.60%	-11.38%	+3.46%	-1.87%	+27.89%
HRMY Harmony Biosciences	+0.63%	-0.11%	+3.91%	+7.32%	+2.32%
SRPT Sarepta Therapeutics	+1.98%	+1.04%	+54.50%	-46.95%	-85.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARVN Arvinas	3.7498 of 5 stars	4.3	3.0	0.0	2.2	2.5	1.3
BLTE Belite Bio	2.5701 of 5 stars	3.5	4.0	0.0	1.5	0.8	0.6
HRMY Harmony Biosciences	4.5403 of 5 stars	3.5	3.0	0.0	2.2	3.3	4.4
SRPT Sarepta Therapeutics	4.5954 of 5 stars	4.0	2.0	4.2	2.4	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.55	Moderate Buy	$19.76	170.73% Upside
BLTE Belite Bio	3.00	Buy	$96.67	48.26% Upside
HRMY Harmony Biosciences	3.00	Buy	$51.00	36.77% Upside
SRPT Sarepta Therapeutics	2.07	Hold	$43.50	116.85% Upside

Current Analyst Ratings Breakdown

Latest ARVN, HRMY, BLTE, and SRPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	SRPT Sarepta Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$17.00
8/15/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$12.00
8/7/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $18.00
8/7/2025	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$19.00 ➝ $16.00
8/7/2025	ARVN Arvinas	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
8/7/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$19.00
8/7/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$48.00 ➝ $50.00
7/29/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$22.00
7/29/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
7/29/2025	SRPT Sarepta Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Perform ➝ Market Perform	$25.00 ➝ $50.00
7/29/2025	SRPT Sarepta Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $20.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$263.40M	2.03	N/A	N/A	$8.30 per share	0.88
BLTE Belite Bio	N/A	N/A	N/A	N/A	$4.71 per share	N/A
HRMY Harmony Biosciences	$714.73M	3.00	$3.02 per share	12.35	$13.44 per share	2.77
SRPT Sarepta Therapeutics	$2.48B	0.79	$2.42 per share	8.28	$13.89 per share	1.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$198.90M	-$1.01	N/A	N/A	N/A	-19.47%	-12.01%	-6.97%	10/29/2025 (Estimated)
BLTE Belite Bio	-$36.14M	-$1.55	N/A	N/A	N/A	N/A	-34.90%	-33.56%	N/A
HRMY Harmony Biosciences	$145.49M	$3.10	12.03	11.99	0.43	23.44%	26.34%	17.71%	11/4/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$0.87	N/A	1.83	N/A	-2.34%	-1.03%	-0.37%	11/5/2025 (Estimated)

Latest ARVN, HRMY, BLTE, and SRPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	BLTE Belite Bio	-$0.47	-$0.50	-$0.03	-$0.50	N/A	N/A
8/6/2025	Q2 2025	ARVN Arvinas	-$0.87	-$0.84	+$0.03	-$0.84	$34.42 million	$22.40 million
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	$2.02	+$1.13	$1.89	$530.66 million	$611.09 million
8/5/2025	Q2 2025	HRMY Harmony Biosciences	$0.78	$0.68	-$0.10	$0.68	$204.37 million	$200.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	5.64	5.64
BLTE Belite Bio	N/A	23.15	23.15
HRMY Harmony Biosciences	0.20	3.84	3.80
SRPT Sarepta Therapeutics	0.84	2.89	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
BLTE Belite Bio	0.53%
HRMY Harmony Biosciences	86.23%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	4.73%
BLTE Belite Bio	13.29%
HRMY Harmony Biosciences	23.60%
SRPT Sarepta Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	73.42 million	69.95 million	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
HRMY Harmony Biosciences	200	57.53 million	43.96 million	Optionable
SRPT Sarepta Therapeutics	1,372	97.71 million	90.29 million	Optionable

ARVN, HRMY, BLTE, and SRPT Headlines

Recent News About These Companies

INVESTOR DEADLINE AUGUST 25: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT

3 hours ago | prnewswire.com

SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline

4 hours ago | globenewswire.com

Sarepta Therapeutics (SRPT): B of A Securities Lowers Price Target | SRPT Stock News

4 hours ago | gurufocus.com

Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SRPT

5 hours ago | globenewswire.com

Sarepta Therapeutics stock falls after refinancing convertible notes

August 21 at 12:44 PM | za.investing.com

Sarepta Therapeutics shares dip after convertible note refinancing

August 21 at 12:44 PM | msn.com

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

August 21 at 12:44 PM | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

August 21 at 10:32 AM | globenewswire.com

Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) - August 25, 2025 Deadline to Join - Contact The Gross Law Firm

August 21 at 8:45 AM | prnewswire.com

SRPT DEADLINE NOTICE: Sarepta Therapeutics, Inc. Investors are Notified of the August 25 Class Action Deadline -- Contact BFA Law if You Suffered Losses (NASDAQ:SRPT)

August 21 at 8:18 AM | globenewswire.com

INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT

August 21 at 7:40 AM | globenewswire.com

Sarepta Therapeutics Restructures Debt with New Convertible Notes

August 21 at 7:30 AM | tipranks.com

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

August 21 at 5:00 AM | prnewswire.com

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

August 21 at 3:54 AM | prnewswire.com

Jim Cramer on Sarepta Therapeutics: “If it Goes Up, You Gotta Do Some Selling”

August 21 at 2:43 AM | finance.yahoo.com

Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients

August 20 at 4:41 PM | msn.com

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 20 at 4:00 PM | globenewswire.com

SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline

August 20 at 3:30 PM | globenewswire.com

Sarepta Therapeutics Faces Regulatory Challenges and Potential Share Price Decline

August 20 at 1:11 PM | tipranks.com

SRPT Investors Have the Opportunity to Lead the Sarepta Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

August 20 at 11:25 AM | globenewswire.com

Nuveen LLC Invests $22.51 Million in Sarepta Therapeutics, Inc. $SRPT

August 20 at 3:51 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARVN, HRMY, BLTE, and SRPT Company Descriptions

Arvinas NASDAQ:ARVN

$7.30 +0.20 (+2.82%)

Closing price 04:00 PM Eastern

Extended Trading

$7.28 -0.02 (-0.34%)

As of 04:20 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Belite Bio NASDAQ:BLTE

$65.20 +1.78 (+2.81%)

Closing price 04:00 PM Eastern

Extended Trading

$65.55 +0.35 (+0.54%)

As of 04:10 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Harmony Biosciences NASDAQ:HRMY

$37.29 +0.66 (+1.80%)

Closing price 04:00 PM Eastern

Extended Trading

$37.33 +0.04 (+0.09%)

As of 05:36 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Sarepta Therapeutics NASDAQ:SRPT

$20.06 -0.52 (-2.53%)

Closing price 04:00 PM Eastern

Extended Trading

$19.83 -0.23 (-1.15%)

As of 07:06 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time